.png){kind=icon}
.png){kind=icon}
Return
Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm
.png){kind=icon}
PRE
AI
B
R
C
M
A
C
C
A
L
B
C
M
C
S
R
G
D
G
M
M
G
M
DOI：10.3324/haematol.2025.288681.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To improve our knowledge on the epidemiological, clinical and pathobiological profile of clonal megakaryocyte dysplasia with normal blood values (CMD-NBV), a BCR::ABL-negative myeloproliferative neoplasms clinical variant, we here report a series of 30 consecutive subjects with CMD-NBV. Sixteen subjects were men and the median age was 48 years (interquartile range [IQR], 39-53 years). A situation-driven diagnosis (70% of cases had the diagnosis triggered by an incidental or symptomatic venous or arterial thrombosis), high incidence of thrombotic events (6.5 events x 100 subject-years), and indolent disease (the 10-year CMD-NBV-specific survival was 100%) were common. Nineteen subjects had a high body mass index at diagnosis and 14 had >= 1 Charlson co-morbidities. In 21 the driver variant was JAK2(V617F) with a median variant allele frequency at diagnosis of 8.9% (IQR, 5.4-18.4%). Six of 24 (25%) subjects with data on next-generation sequencing for myeloid neoplasm-related genes had >= 1 pathogenic somatic variant in ASXL1, TET2, DNMT3A or SRSF2, a frequency in the lower range of values of chronic myeloproliferative neoplasms. Twelve putative germline, non-pathogenic, missense variants in ASXL1, TET2, DNMT3A, RUNX1, CUX1, ABL1, NF1, KIT and CSF3R or 5' UTR in NF1 and 3' UTR in ASXL1 were detected in ten of 24 (42%) subjects. These data further support identification of CMD-NBV as a distinct entity.
Keywords:
WORLD-HEALTH-ORGANIZATION
JAK2V617F MUTATION
CLASSIFICATION
VARIANTS
ABSENCE
RISK
Journal
IF:
7.9
Papers:
6.4K
Citations:
2.2W
Organization
Cited Papers